美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

賽生藥業

11.15

0.0000

成交量：- -

成交額：- -

市值：5.82億

市盈率：13.60

高：11.15

開：11.15

低：11.15

收：11.15

52周最高：11.43

52周最低：8.55

股本：5,219.20萬

流通股本：4,527.09萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):0.8200

淨資產收益率：--

總資產收益率：--

市淨率：2.33

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

港股異動 | 賽生藥業大漲9% 達佑澤的生物製品許可申請獲國家藥監局批准

金融界网站

【港股通】賽生藥業(06600)拉升12.38% 達佑澤生物製品許可申請治療高危神經母細胞瘤患者獲批

凤凰网港股

港股異動 | 賽生藥業(06600)拉升逾10% 那西妥單抗注射液獲批上市用於治療神經母細胞瘤

中金：維持賽生藥業(06600)「跑贏行業」評級目標價11港元

賽生藥業宣佈達佑澤®（那西妥單抗）在中國獲批

【港股通】賽生藥業(06600)：達佑澤的生物製品許可申請獲藥監局批准正為商業化進行準備工作

凤凰网港股

賽生藥業(06600)：達佑澤®的生物製品許可申請獲國家藥監局批准在中國治療複發性或難治性高危神經母細胞瘤患者

賽生藥業(06600.HK)「達佑澤」生物製品許可申請獲批

阿斯达克财经

港股異動 | 賽生藥業(06600)放量跌13% 主要機構股東中央匯金減持100萬股

智通财经网

【港股通】賽生藥業(06600)跌近12% 遭股東減持100萬股

凤凰网港股

搭後疫情快車，賽生藥業(06600)的胸腺法新「一招鮮」能吃多久？

《全日速報》恒指全日收報19,441點跌77點; 恒生科技指數全日收報4,161點跌76點阿里巴巴跌逾3% 賽生藥業、永利澳門、美高梅中國、首程控股創新高成交暢旺

阿斯达克财经

《半日速報》恒指半日收報19,336點跌181點; 恒生科技指數半日收報4,156點跌81點平安跌逾5% 阿里巴巴跌逾3% 賽生藥業、美高梅中國、永利澳門、固生堂、首程控股創新高

阿斯达克财经

【港股通】賽生藥業(06600)漲逾24% 旗下日達仙獲納入用於新冠治療指南

凤凰网港股

賽生藥業(6600.HK)一度漲44% 旗下日達仙獲納入新冠治療用藥

金融界网站

港股異動 | 賽生藥業(06600)升40% 北水持倉增至2% 旗下日達仙為新冠治療用藥

賽生藥業(06600.HK)11月30日耗資63.3萬港元回購10萬股

金融界网站

賽生藥業(06600)11月30日斥資約63.32萬港元回購10萬股

賽生藥業(06600.HK)11月24日耗資32.8萬港元回購5萬股

金融界网站

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SCLN/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SCLN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCLN\",,,,,undefined,":{"symbol":"SCLN","market":"US","secType":"STK","nameCN":"賽生藥業","latestPrice":11.15,"timestamp":1515186000000,"preClose":11.15,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":45270936,"shares":52192000,"eps":0.82,"marketStatus":"未開盤","change":0,"latestTime":"01-05 16:00:00 EST","open":11.15,"high":11.15,"low":11.15,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.82,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1775548800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":700808400000,"exchange":"NASDAQ","adjPreClose":11.15,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCLN\",,,,,undefined,":{"symbol":"SCLN","floatShares":45270936,"roa":"--","roe":"--","lyrEps":0,"shares":52192000,"dividePrice":0,"high":11.15,"amplitude":0,"preClose":11.15,"low":11.15,"week52Low":8.55,"pbRate":"2.33","week52High":11.425,"institutionHeld":0.4567,"latestPrice":11.15,"eps":0.82,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.82,"open":11.15,"prevYearClose":11.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCLN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-08-09","symbol":"SCLN","fiscalQuarterEnding":"2017/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1502251200000,"reportTimeType":"post","actualEps":0.26},{"market":"US","date":"2017-05-10","symbol":"SCLN","fiscalQuarterEnding":"2017/03","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1494388800000,"reportTimeType":"post","actualEps":0.29},{"market":"US","date":"2017-03-06","symbol":"SCLN","fiscalQuarterEnding":"2016/12","expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1488776400000,"reportTimeType":"pre","actualEps":0.17},{"market":"US","date":"2016-11-09","symbol":"SCLN","fiscalQuarterEnding":"2016/09","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1478667600000,"reportTimeType":"post","actualEps":0.19},{"market":"US","date":"2016-08-09","symbol":"SCLN","fiscalQuarterEnding":"2016/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1470715200000,"reportTimeType":"","actualEps":0.18}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCLN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCLN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SCLN\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2290247719","title":"港股異動 | 賽生藥業大漲9% 達佑澤的生物製品許可申請獲國家藥監局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2290247719","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2290247719?lang=zh_tw&edition=fundamental","pubTime":"2022-12-09 11:03","pubTimestamp":1670554997,"startTime":"0","endTime":"0","summary":"格隆汇12月9日丨赛生药业大涨9%，报8.72港元，总市值60亿港元。赛生药业昨日发布公告，国家药监局已批准达佑泽?(那西妥单抗)的生物制品许可申请(“BLA”)，其与粒细胞―巨噬细胞集落刺激因子(“GM-CSF”)联合给药，用于治疗伴有骨或骨髓病变，对既往治疗表现为部分缓解、轻微缓解或疾病稳定的1岁及以上儿童或成年复发性或难治性高危神经母细胞瘤患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2022/12/09110337200688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","SCLN","06600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2290372472","title":"【港股通】賽生藥業(06600)拉升12.38% 達佑澤生物製品許可申請治療高危神經母細胞瘤患者獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2290372472","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2290372472?lang=zh_tw&edition=fundamental","pubTime":"2022-12-09 10:55","pubTimestamp":1670554504,"startTime":"0","endTime":"0","summary":"赛生药业(06600)结束连续两日下跌走势，盘中持续冲高，最新报8.98港元，涨12.38%，成交额1.03亿港元。公司公布，国家药监局已批准达佑泽(那西妥单抗)的生物制品许可申请(BLA)，其与粒细胞—巨噬细胞集落刺激因子(GM-CSF)联合给药，用于治疗伴有骨或骨髓病变，对既往治疗表现为部分缓解、轻微缓解或疾病稳定的1岁及以上儿童或成年复发性或难治性高危神经母细胞瘤患者。达佑泽获国家药监局批准将为更多国内复发性或难治性高危神经母细胞瘤患者带来新的有效治疗选择。公司正为达佑泽于2023年于中国开始商业化进行准备工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=b10644e9823347a0a20ae57c96b60676","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06600","SCLN","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2290723834","title":"港股異動 | 賽生藥業(06600)拉升逾10% 那西妥單抗注射液獲批上市 用於治療神經母細胞瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2290723834","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2290723834?lang=zh_tw&edition=fundamental","pubTime":"2022-12-09 10:49","pubTimestamp":1670554189,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛生药业(06600)盘中拉升逾11%，截至发稿，11.25%，报8.9港元，成交额1.05亿港元。消息面上，赛生药业发布公告，国家药监局已批准达佑泽®(那西妥单抗)的生物制品许可申请(“BLA”)，其与粒细胞—巨噬细胞集落刺激因子(“GM-CSF”)联合给药，用于治疗伴有骨或骨髓病变，对既往治疗表现为部分缓解、轻微缓解或疾病稳定的1岁及以上儿童或成年复发性或难治性高危神经母细胞瘤患者。中金发布研究报告称，维持赛生药业“跑赢行业”评级，目标价11港元。公司核心品种增长稳健，持续贡献稳定现金流。同时增量业务围绕优势科室拓展布局，逐步进入放量期。并且主业盈利能力总体稳定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/844720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06600","SCLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2290479923","title":"中金：維持賽生藥業(06600)「跑贏行業」評級 目標價11港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2290479923","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2290479923?lang=zh_tw&edition=fundamental","pubTime":"2022-12-09 09:18","pubTimestamp":1670548703,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研究报告称，维持赛生药业“跑赢行业”评级，2022-23年盈利预测不变，目标价11港元，较当前股价有37.5%上行空间。此外，公司于12月8日公告达佑泽获国家药监局批准，用于复发难治性高危神经母细胞瘤患者治疗。中金主要观点如下：核心品种增长稳健，持续贡献稳定现金流。存量核心产品日达仙在国家集采未中标及高基数的背景下维持增长，1H22收入同比增长7.0%，持续为公司提供现金流。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/844668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SCLN","06600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2289498284","title":"賽生藥業宣佈達佑澤®（那西妥單抗）在中國獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2289498284","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2289498284?lang=zh_tw&edition=fundamental","pubTime":"2022-12-08 21:40","pubTimestamp":1670506800,"startTime":"0","endTime":"0","summary":"2021年9月，赛生药业在中国澳门递交达佑泽的上市申请。达佑泽在中国正式获批，将为国内神经母细胞瘤患儿带来全新有效的治疗选择，为他们的家庭带来更多希望。2021年7月，达佑泽在美国获批上市仅七个多月后，赛生药业即向NMPA 递交达佑泽的BLA并获受理。2022年1月，赛生药业根据当地特殊进口政策在中国台湾销售达佑泽，进一步扩大其在大中华地区的可及性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/3960144_ZH60144_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1191","SCLN","06600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2289417125","title":"【港股通】賽生藥業(06600)：達佑澤的生物製品許可申請獲藥監局批准 正為商業化進行準備工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2289417125","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2289417125?lang=zh_tw&edition=fundamental","pubTime":"2022-12-08 19:20","pubTimestamp":1670498412,"startTime":"0","endTime":"0","summary":"赛生药业发布公告，中国国家药监局已批准达佑泽的生物制品许可申请，其与粒细胞—巨噬细胞集落刺激因子联合给药，用于治疗伴有骨或骨髓病变，对既往治疗表现为部分缓解、轻微缓解或疾病稳定的1岁及以上儿童或成年复发性或难治性高危神经母细胞瘤患者。公司正为达佑泽于2023年于中国开始商业化进行准备工作。2021年9月，赛生药业在中国澳门递交达佑泽的上市申请。于2022年1月，赛生药业根据当地特殊进口政策在中国台湾销售达佑泽。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=2180104d2be9856b04233942c42c34b8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06600","SCLN","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2289419923","title":"賽生藥業(06600)：達佑澤®的生物製品許可申請獲國家藥監局批准在中國治療複發性或難治性高危神經母細胞瘤患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2289419923","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2289419923?lang=zh_tw&edition=fundamental","pubTime":"2022-12-08 17:26","pubTimestamp":1670491570,"startTime":"0","endTime":"0","summary":"达佑泽是目前全球唯一一款获批的靶向双唾液酸神经节苷脂GD2的人源化单克隆抗体，其在复发性或难治性高危神经母细胞瘤的疗效和安全性已获现有临床研究结果证实。达佑泽获国家药监局批准将为更多国内复发性或难治性高危神经母细胞瘤患者带来新的有效治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/844298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06600","BK1191","SCLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2289419177","title":"賽生藥業(06600.HK)「達佑澤」生物製品許可申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2289419177","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2289419177?lang=zh_tw&edition=fundamental","pubTime":"2022-12-08 17:23","pubTimestamp":1670491380,"startTime":"0","endTime":"0","summary":"赛生药业(06600.HK) 公布，国家药监局近日已批准公司旗下“达佑泽”(那西妥单抗)的生物制品许可申请，其与粒细胞—巨噬细胞集落刺激因子(GM-CSF)联合给药，可用于治疗伴有骨或骨髓病变，对既往治疗表现为部分缓解、轻微缓解或疾病稳定的1岁及以上儿童或成年复发性或难治性高危神经母细胞瘤患者。赛生药业表示，去年9月已在澳门递交达佑泽的上市申请，并于今年1月根据当地特殊进口政策于台湾地区销售达佑泽，未来亦将积极寻求扩大使用达佑泽可能解决的疾病适应症。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2022-12-08 16:25。)","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220104144609209_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220104144609209_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1232098/latest-news/HK6","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1232098/latest-news/HK6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["SCLN","BK1191","06600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2289649973","title":"港股異動 | 賽生藥業(06600)放量跌13% 主要機構股東中央匯金減持100萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2289649973","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2289649973?lang=zh_tw&edition=fundamental","pubTime":"2022-12-08 11:59","pubTimestamp":1670471958,"startTime":"0","endTime":"0","summary":"赛生药业(06600)连续两日调整，早盘跌13%，当前成交量创去年3月上市以来新高。本周一，赛生药业收升36%，当日，股东中央汇金进场减持100万股。中央汇金是公司IPO前重要股东，17年曾以财团身份参与公司美股私有化退市行动。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20221208/20221208121631_77791.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20221208/20221208121631_77791.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/844061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["SCLN","06600","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2289741460","title":"【港股通】賽生藥業(06600)跌近12% 遭股東減持100萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2289741460","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2289741460?lang=zh_tw&edition=fundamental","pubTime":"2022-12-08 09:44","pubTimestamp":1670463861,"startTime":"0","endTime":"0","summary":"赛生药业(06600)连续第二日回落，早盘股价继续走低，最新报8.14港元，跌11.9%，成交额3.19亿港元。值得注意的是，该股此前两日曾升近60%。消息面上，赛生药业股东Central Huijin于12月5日场内减持100万股，占发行股数0.15%，场内平均作价8.2685港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=c52589fbd4a0b8fcfabad61c13be3fdb","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCLN","BK1191","06600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2289798147","title":"搭後疫情快車，賽生藥業(06600)的胸腺法新「一招鮮」能吃多久？","url":"https://stock-news.laohu8.com/highlight/detail?id=2289798147","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2289798147?lang=zh_tw&edition=fundamental","pubTime":"2022-12-06 18:49","pubTimestamp":1670323784,"startTime":"0","endTime":"0","summary":"驱动赛生药业业绩增长的最大动力便是其自有产品日达仙。由双成药业生产的胸腺法新仿制药基泰于2020年12月通过一致性评价，另有四种其他胸腺法新仿制药待一致性评价。加之目前后疫情时代潜在的市场增量，赛生药业或能在后续实现企业支柱型产品遭受集采及仿制药冲击后业绩的软着陆及进一步增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/843001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SCLN","BK1191","06600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2289145085","title":"《全日速報》恒指全日收報19,441點 跌77點; 恒生科技指數全日收報4,161點 跌76點 阿里巴巴跌逾3% 賽生藥業、永利澳門、美高梅中國、首程控股創新高 成交暢旺","url":"https://stock-news.laohu8.com/highlight/detail?id=2289145085","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2289145085?lang=zh_tw&edition=fundamental","pubTime":"2022-12-06 16:12","pubTimestamp":1670314320,"startTime":"0","endTime":"0","summary":"恒指全日收19,441点，跌77点或0.4%。恒生科技指数报4,161点，跌76点或1.8%。国指跌53点或0.8%，报6,652点。大市成交额1,650.04亿元。沽空资料截至 2022-12-06 12:25。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180305131110113_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180305131110113_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1231478/latest-news/HK6","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1231478/latest-news/HK6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK4527","BK4548","02282","HHImain","IE00B0JY6N72.USD","BK4524","LU1688375341.USD","LU1046422090.SGD","BK4534","BK4122","BK4526","BK4565","06600","HSI","01128","BK4502","BK1589","BK1191","BK4505","09988","BK1172","00697","BK1216","HSTECH","MCHmain","BABA","BK4503","BK4531","BK4538","513600","QNETCN","BK4581","BK4535","SCLN","BK4558","BK4504","BK4554","BK4533","BK4579","LU0251143458.SGD","02833","BK4575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2289114343","title":"《半日速報》恒指半日收報19,336點 跌181點; 恒生科技指數半日收報4,156點 跌81點 平安跌逾5% 阿里巴巴跌逾3% 賽生藥業、美高梅中國、永利澳門、固生堂、首程控股創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2289114343","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2289114343?lang=zh_tw&edition=fundamental","pubTime":"2022-12-06 12:12","pubTimestamp":1670299920,"startTime":"0","endTime":"0","summary":"恒指半日收19,336点，跌181点或0.9%。恒生科技指数报4,156点，跌81点或1.9%。国指跌91点或1.4%，报6,614点。沽空资料截至 2022-12-05 16:25。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1231438/latest-news/HK6","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1231438/latest-news/HK6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK4535","LU1046422090.SGD","BK4558","BK1219","00697","BK1172","QNETCN","IE00B0JY6N72.USD","02282","01128","06600","BK4502","BK1191","BK4122","SCLN","BABA","BK4581","BK4524","BK4548","BK4534","09988","513600","BK4554","MCHmain","BK4527","BK4504","BK1216","02273","BK4538","HSTECH","02833","BK4503","BK4575","HSI","LU0251143458.SGD","LU1688375341.USD","BK4526","BK4531","BK1589","BK4579","HHImain","BK4533","BK4505","BK4565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2289197691","title":"【港股通】賽生藥業(06600)漲逾24% 旗下日達仙獲納入用於新冠治療指南","url":"https://stock-news.laohu8.com/highlight/detail?id=2289197691","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2289197691?lang=zh_tw&edition=fundamental","pubTime":"2022-12-06 11:13","pubTimestamp":1670296427,"startTime":"0","endTime":"0","summary":"赛生药业(06600)延续昨日强劲升势，今日早盘一度涨至44%，随后回稳，现涨24.66%，报10.36港元，成交额1.89亿港元。值得注意的是，该股两日累计涨幅超68%。消息面上，据媒体报道，该公司旗下核心自研产品日达仙已被纳入国家卫健委、中华医学会等专业协会发布的治疗指南，用于脓毒症、胰腺癌、肝癌、COVID-19以及胃癌等的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=58c1890b8c185f3bf7ad441cdf7e8cdf","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","06600","SCLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2289329116","title":"賽生藥業(6600.HK)一度漲44% 旗下日達仙獲納入新冠治療用藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2289329116","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2289329116?lang=zh_tw&edition=fundamental","pubTime":"2022-12-06 10:07","pubTimestamp":1670292429,"startTime":"0","endTime":"0","summary":"格隆汇12月6日丨 赛生药业(6600.HK)盘中一度涨超44%至12港元。该公司旗下核心自研产品日达仙已被纳入国家卫健委、中华医学会等专业协会发布的治疗指南，用于脓毒症、胰腺癌、肝癌、COVID-19以及胃癌等的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2022/12/06100737191094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","SCLN","06600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2289134272","title":"港股異動 | 賽生藥業(06600)升40% 北水持倉增至2% 旗下日達仙為新冠治療用藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2289134272","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2289134272?lang=zh_tw&edition=fundamental","pubTime":"2022-12-05 13:59","pubTimestamp":1670219951,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛生药业日内放量回升，午后升约40%。目前，赛生药业北水持仓占比已增至2%。公司旗下免疫调节剂药物日达仙，用于胰腺癌、肝癌、新冠肺炎等的治疗，收入占比达到80%。截至发稿，赛生药业涨39.80%，报8.57港元，成交额1.22亿港元。联交所数据显示，近三个月，南下资金加仓赛生药业约1个百分点，截至12月2日，持仓占比为2.03%。赛生药业旗下核心自研产品日达仙，是我国首个品牌胸腺法新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/842007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","06600","SCLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2287664134","title":"賽生藥業(06600.HK)11月30日耗資63.3萬港元回購10萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2287664134","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2287664134?lang=zh_tw&edition=fundamental","pubTime":"2022-11-30 20:44","pubTimestamp":1669812286,"startTime":"0","endTime":"0","summary":"格隆汇11月30日丨赛生药业(06600.HK)公告，11月30日耗资63.3万港元回购10万股，每股价格为6.29-6.4港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2022/11/30204437179467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06600","SCLN","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2287566661","title":"賽生藥業(06600)11月30日斥資約63.32萬港元回購10萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2287566661","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2287566661?lang=zh_tw&edition=fundamental","pubTime":"2022-11-30 20:44","pubTimestamp":1669812267,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛生药业(06600)发布公告，于2022年11月30日斥资约63.32万港元回购股份10万股，每股回购价格为6.29-6.4港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/840085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","SCLN","06600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2285150385","title":"賽生藥業(06600.HK)11月24日耗資32.8萬港元回購5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2285150385","media":"金融界网站","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2285150385?lang=zh_tw&edition=fundamental","pubTime":"2022-11-24 18:59","pubTimestamp":1669287592,"startTime":"0","endTime":"0","summary":"格隆汇11月24日丨赛生药业(06600.HK)公告，11月24日耗资32.8万港元回购5万股，每股价格为6.6-6.51港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.jrj.com.cn/2022/11/24185937164614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","SCLN","06600"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":86,"code":"91000000","status":"200"}]}}